KPV: The Anti-Inflammatory Tripeptide and Its Role in Gut Health
KPV is a tripeptide derived from alpha-MSH and investigated in inflammatory-signalling research, with limits when applying findings to human care.
By UAE Peptide Clinic Research Desk
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-MSH (alpha-melanocyte-stimulating hormone). Where alpha-MSH is a 13-amino-acid peptide with broad melanocortin activity, KPV retains the anti-inflammatory properties of its parent molecule in a far smaller and more stable form. It is one of the most studied peptides in gastrointestinal inflammation research, including inflammatory bowel disease models.
Mechanism of Action
Research suggests KPV acts through multiple pathways: studies report inhibition of pro-inflammatory cytokine production (including IL-6, TNF-alpha, and IL-1beta), activation of melanocortin receptors at peripheral and intestinal sites, and modulation of NF-kB signalling, a master regulator of the inflammatory response. Its reported intestinal action is why it is studied in gut inflammation, where systemic immunosuppression would be a broad intervention.
Areas of Research
KPV has been studied in relation to inflammatory bowel conditions (Crohn's disease, ulcerative colitis), gut permeability and intestinal barrier function, and systemic inflammation. Its small size has led researchers to examine oral delivery with localised intestinal action, though systemic administration is also studied. It is sometimes discussed alongside BPC-157 in gut research.
- Tripeptide derived from alpha-MSH, highly stable
- Studied for inhibition of IL-6, TNF-alpha and IL-1beta
- Researched for direct intestinal anti-inflammatory action
- Often discussed alongside BPC-157 in gut research
If you want to understand whether any of this is relevant to you, an independent DHA-licensed physician can review your case. Take the two-minute quiz at /find-my-stack or book a physician consultation at /book (AED 300 deposit, credited to your first order).
